Abbvie Inc
NYSE: ABBV
$164.99
-$4.64 (-2.7%)
Closing Price on November 15, 2024
ABBV Articles
Buying stocks such as these, with solid growth potential and paying dividends higher than the 10-year Treasury debt, makes good sense now.
Published:
Last Updated:
Tuesday's top analyst upgrades, downgrades and initiations include AbbVie, Apple, Autodesk, JD.com, CyberArk, Dean Foods and Walt Disney.
Published:
Last Updated:
AbbVie reported better-than-expected third-quarter financial results before the markets opened on Friday.
Published:
Last Updated:
AbbVie is expected to report its third-quarter financial results before the markets open on Friday.
Published:
Gilead Sciences is set to report its third-quarter financial results after the markets close on Thursday.
Published:
The October 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest was mixed.
Published:
Each week we cover the new value calls from the analysts at Jefferies, and more and more, some of the calls may look surprising.
Published:
These biotech stocks 24/7 Wall St. has picked stood out from the rest with at least 25% gains over the course of the past week.
Published:
Friday's top analyst upgrades, downgrades and initiations include AbbVie, Alphabet, Amazon.com, American Electric Power, Apple, Microsoft, Pandora Media and McDonald's.
Published:
ThinkstockThe U.S. Food and Drug Administration (FDA) issued a warning that hepatitis C treatments, Viekira Pak and Technivie, can cause serious liver injury mostly in patients with underlying...
Published:
Last Updated:
These Jefferies Franchise picks with solid dividends are perfect for long-term accounts that like to employ a buy-and-hold strategy.
Published:
The September 30 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest was mixed.
Published:
Credit Suisse is adding some top conservative dividend-paying stocks to its Top Picks list, and that is right in line with what other top Wall Street firms are doing.
Published:
The September 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest has increased.
Published:
The short interest data have been released for the August 31 settlement date, and for the selected pharmaceutical stocks, short interest is mixed.
Published: